Relapsed And Refractory Multiple Myeloma clinical trials

Explore recruiting relapsed and refractory multiple myeloma clinical trials.

Recruiting relapsed and refractory multiple myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed And Refractory Multiple Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A trial to test if different amounts of KTX-1001 are safe and tolerable in people with the bone marrow cancer multiple myeloma that has come back or where treatment did not work.

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

Belgium, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Spain, Italy, Belgium, Netherlands, Germany, France +1 more

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment And is not Responsive After Treatment.

Spain, Germany, Sweden, Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma

Spain, Greece, Italy, Germany, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapsed And Refractory Multiple Myeloma trials by city

Relapsed And Refractory Multiple Myeloma in Toronto Relapsed And Refractory Multiple Myeloma in Vancouver Relapsed And Refractory Multiple Myeloma in Montreal Relapsed And Refractory Multiple Myeloma in Calgary Relapsed And Refractory Multiple Myeloma in Edmonton Relapsed And Refractory Multiple Myeloma in Ottawa Relapsed And Refractory Multiple Myeloma in Winnipeg Relapsed And Refractory Multiple Myeloma in Quebec City Relapsed And Refractory Multiple Myeloma in Hamilton Relapsed And Refractory Multiple Myeloma in Kitchener Relapsed And Refractory Multiple Myeloma in London Relapsed And Refractory Multiple Myeloma in Halifax Relapsed And Refractory Multiple Myeloma in New York Relapsed And Refractory Multiple Myeloma in Los Angeles Relapsed And Refractory Multiple Myeloma in Chicago Relapsed And Refractory Multiple Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease